
Onconova Therapeutics (ONTX) Stock Forecast & Price Target
Onconova Therapeutics (ONTX) Analyst Ratings
Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%
Onconova Therapeutics (ONTX) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.
This aggregate rating is based on analysts' research of Onconova Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
This aggregate rating is based on analysts' research of Onconova Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Onconova Therapeutics (ONTX) Analyst Forecast & Price Prediction
Get the latest Onconova Therapeutics (ONTX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Start investing in Onconova Therapeutics (ONTX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Onconova Therapeutics (ONTX) Forecast
Analysts have given Onconova Therapeutics (ONTX) a Strong Buy based on their latest research and market trends.
According to 8 analysts, Onconova Therapeutics (ONTX) has a Strong Buy consensus rating as of Jul 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.
Wall Street analysts have set a price target of $14.88, reflecting a 0.00% increase from the current stock price.
Financial analysts have set a price target of $14.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.